Inspire Medical Systems (NYSE:INSP) Price Target Cut to $248.00 by Analysts at Robert W. Baird

Inspire Medical Systems (NYSE:INSP) had its price objective decreased by Robert W. Baird from $252.00 to $248.00 in a research note released on Tuesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other equities research analysts have also commented on the company. Wells Fargo & Company dropped their price target on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and issued a $260.00 target price on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Piper Sandler dropped their target price on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a research report on Monday. Morgan Stanley dropped their target price on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Stifel Nicolaus decreased their price target on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research note on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $228.82.

Inspire Medical Systems Stock Up 1.2 %

Inspire Medical Systems stock opened at $183.17 on Tuesday. The business’s 50-day simple moving average is $189.57 and its 200 day simple moving average is $190.98. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of 171.18 and a beta of 1.32. Inspire Medical Systems has a 12-month low of $123.00 and a 12-month high of $257.40.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. As a group, sell-side analysts expect that Inspire Medical Systems will post 1.33 EPS for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

A number of institutional investors have recently modified their holdings of INSP. First Horizon Advisors Inc. increased its holdings in Inspire Medical Systems by 885.7% in the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 124 shares in the last quarter. True Wealth Design LLC acquired a new position in Inspire Medical Systems in the 3rd quarter worth about $30,000. Farther Finance Advisors LLC increased its holdings in Inspire Medical Systems by 1,158.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after purchasing an additional 139 shares in the last quarter. GAMMA Investing LLC increased its holdings in Inspire Medical Systems by 559.3% in the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock worth $38,000 after purchasing an additional 151 shares in the last quarter. Finally, Harbour Investments Inc. increased its holdings in Inspire Medical Systems by 101.0% in the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock worth $37,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.